U.S. Biotech/Pharma Sector Daily Observations Letter: January 17, 2018


Exact Sciences fell from its recent highs after the report of a new blood test that could have a higher sensitivity to detect precancerous lesions. Watching Exact Sciences fall from its recent highs after the report of a new blood test that could have a higher sensitivity to detect precancerous lesions than the company's stool-based cologuard test.



from Biotech News